InvestorsHub Logo
Followers 94
Posts 11186
Boards Moderated 0
Alias Born 11/02/2003

Re: None

Friday, 08/06/2021 7:52:10 AM

Friday, August 06, 2021 7:52:10 AM

Post# of 325
NEWS -- Oncolytics Biotech® Reports 2021 Second Quarter Development Highlights and Financial Results
  • Clinical AWARE-1 trial achieves primary endpoint and confirms that pelareorep is an immunotherapeutic agent which synergizes with checkpoint inhibitors: Validation of clinical development strategy in breast cancer
  • Phase 2 BRACELET-1 (breast cancer) trial remains on track for full enrollment in Q4 2021
  • Highly encouraging clinical proof-of-concept data in metastatic pancreatic cancer demonstrate pelareorep's broad applicability to a number of different tumor types
  • Strong financial foundation with approximately $50.8 million in cash on hand and cash runway into 2023
  • Management hosting conference call and webcast today at 8:00 a.m. ET
To view full Press Release click: https://www.prnewswire.com/news-releases/oncolytics-biotech-reports-2021-second-quarter-development-highlights-and-financial-results-301350059.html
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent ONCY News